Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection

Ian Elliott Brown, Christian Blank, Justin Kline, Aalok K. Kacha, Thomas F. Gajewski

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Although recent work has suggested that lymphopenia-induced homeostatic proliferation may improve T cell-mediated tumor rejection, there is little direct evidence isolating homeostatic proliferation as an experimental variable, and the mechanism by which improved antitumor immunity occurs via homeostatic proliferation is poorly understood. An adoptive transfer model was developed in which tumor-specific 2C/RAG2-/- TCR transgenic CD8+ T cells were introduced either into the lymphopenic environment of RAG2 -/- mice or into P14/RAG2-/- mice containing an irrelevant CD8+ TCR transgenic population. RAG2-/-, but not P14/RAG2-/- recipients supported homeostatic proliferation of transferred T cells as well as tumor rejection. Despite absence of tumor rejection in P14/RAG2-/- recipients, 2C cells did become activated, as reflected by CFSE dilution and CD44 up-regulation. However, these cells showed poor IFN-γ and IL-2 production upon restimulation, consistent with T cell anergy and similar to the hyporesponsiveness induced by administration of soluble peptide Ag. To determine whether homeostatic proliferation could uncouple T cell anergy, anergic 2C cells were transferred into RAG-/- recipients, which resulted in vigorous homeostatic proliferation, recovery of IL-2 production, and acquisition of the ability to reject tumors. Taken together, our data suggest that a major mechanism by which homeostatic proliferation supports tumor rejection is by maintaining and/or reestablishing T cell responsiveness.

Original languageEnglish (US)
Pages (from-to)4521-4529
Number of pages9
JournalJournal of Immunology
Volume177
Issue number7
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

T-Lymphocytes
Neoplasms
Interleukin-2
Lymphopenia
Adoptive Transfer
Immunity
Up-Regulation
Peptides
Population

ASJC Scopus subject areas

  • Immunology

Cite this

Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. / Brown, Ian Elliott; Blank, Christian; Kline, Justin; Kacha, Aalok K.; Gajewski, Thomas F.

In: Journal of Immunology, Vol. 177, No. 7, 01.10.2006, p. 4521-4529.

Research output: Contribution to journalArticle

Brown, Ian Elliott ; Blank, Christian ; Kline, Justin ; Kacha, Aalok K. ; Gajewski, Thomas F. / Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. In: Journal of Immunology. 2006 ; Vol. 177, No. 7. pp. 4521-4529.
@article{1ac7264cc81045acb0d39583413bb9a0,
title = "Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection",
abstract = "Although recent work has suggested that lymphopenia-induced homeostatic proliferation may improve T cell-mediated tumor rejection, there is little direct evidence isolating homeostatic proliferation as an experimental variable, and the mechanism by which improved antitumor immunity occurs via homeostatic proliferation is poorly understood. An adoptive transfer model was developed in which tumor-specific 2C/RAG2-/- TCR transgenic CD8+ T cells were introduced either into the lymphopenic environment of RAG2 -/- mice or into P14/RAG2-/- mice containing an irrelevant CD8+ TCR transgenic population. RAG2-/-, but not P14/RAG2-/- recipients supported homeostatic proliferation of transferred T cells as well as tumor rejection. Despite absence of tumor rejection in P14/RAG2-/- recipients, 2C cells did become activated, as reflected by CFSE dilution and CD44 up-regulation. However, these cells showed poor IFN-γ and IL-2 production upon restimulation, consistent with T cell anergy and similar to the hyporesponsiveness induced by administration of soluble peptide Ag. To determine whether homeostatic proliferation could uncouple T cell anergy, anergic 2C cells were transferred into RAG-/- recipients, which resulted in vigorous homeostatic proliferation, recovery of IL-2 production, and acquisition of the ability to reject tumors. Taken together, our data suggest that a major mechanism by which homeostatic proliferation supports tumor rejection is by maintaining and/or reestablishing T cell responsiveness.",
author = "Brown, {Ian Elliott} and Christian Blank and Justin Kline and Kacha, {Aalok K.} and Gajewski, {Thomas F.}",
year = "2006",
month = "10",
day = "1",
language = "English (US)",
volume = "177",
pages = "4521--4529",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "7",

}

TY - JOUR

T1 - Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection

AU - Brown, Ian Elliott

AU - Blank, Christian

AU - Kline, Justin

AU - Kacha, Aalok K.

AU - Gajewski, Thomas F.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Although recent work has suggested that lymphopenia-induced homeostatic proliferation may improve T cell-mediated tumor rejection, there is little direct evidence isolating homeostatic proliferation as an experimental variable, and the mechanism by which improved antitumor immunity occurs via homeostatic proliferation is poorly understood. An adoptive transfer model was developed in which tumor-specific 2C/RAG2-/- TCR transgenic CD8+ T cells were introduced either into the lymphopenic environment of RAG2 -/- mice or into P14/RAG2-/- mice containing an irrelevant CD8+ TCR transgenic population. RAG2-/-, but not P14/RAG2-/- recipients supported homeostatic proliferation of transferred T cells as well as tumor rejection. Despite absence of tumor rejection in P14/RAG2-/- recipients, 2C cells did become activated, as reflected by CFSE dilution and CD44 up-regulation. However, these cells showed poor IFN-γ and IL-2 production upon restimulation, consistent with T cell anergy and similar to the hyporesponsiveness induced by administration of soluble peptide Ag. To determine whether homeostatic proliferation could uncouple T cell anergy, anergic 2C cells were transferred into RAG-/- recipients, which resulted in vigorous homeostatic proliferation, recovery of IL-2 production, and acquisition of the ability to reject tumors. Taken together, our data suggest that a major mechanism by which homeostatic proliferation supports tumor rejection is by maintaining and/or reestablishing T cell responsiveness.

AB - Although recent work has suggested that lymphopenia-induced homeostatic proliferation may improve T cell-mediated tumor rejection, there is little direct evidence isolating homeostatic proliferation as an experimental variable, and the mechanism by which improved antitumor immunity occurs via homeostatic proliferation is poorly understood. An adoptive transfer model was developed in which tumor-specific 2C/RAG2-/- TCR transgenic CD8+ T cells were introduced either into the lymphopenic environment of RAG2 -/- mice or into P14/RAG2-/- mice containing an irrelevant CD8+ TCR transgenic population. RAG2-/-, but not P14/RAG2-/- recipients supported homeostatic proliferation of transferred T cells as well as tumor rejection. Despite absence of tumor rejection in P14/RAG2-/- recipients, 2C cells did become activated, as reflected by CFSE dilution and CD44 up-regulation. However, these cells showed poor IFN-γ and IL-2 production upon restimulation, consistent with T cell anergy and similar to the hyporesponsiveness induced by administration of soluble peptide Ag. To determine whether homeostatic proliferation could uncouple T cell anergy, anergic 2C cells were transferred into RAG-/- recipients, which resulted in vigorous homeostatic proliferation, recovery of IL-2 production, and acquisition of the ability to reject tumors. Taken together, our data suggest that a major mechanism by which homeostatic proliferation supports tumor rejection is by maintaining and/or reestablishing T cell responsiveness.

UR - http://www.scopus.com/inward/record.url?scp=33749135271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749135271&partnerID=8YFLogxK

M3 - Article

C2 - 16982889

AN - SCOPUS:33749135271

VL - 177

SP - 4521

EP - 4529

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 7

ER -